This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Sanofi (SNY) Gets FDA Approval for Sarclisa Label Expansion
by Zacks Equity Research
Sanofi's (SNY) Sarclisa gets FDA approval to treat multiple myeloma patients who have received one to three prior lines of therapy in combination with Kyprolis and dexamethasone.
Translate (TBIO) Down on Unsatisfactory CF Drug Study Results
by Zacks Equity Research
Translate Bio (TBIO) announces data from second interim analysis of phase I/II study evaluating MRT5005 in patients with cystic fibrosis. The candidate fails to improve lung function in patients.
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron Pharma, Sanofi, Novavax and Translate Bio
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron Pharma, Sanofi, Novavax and Translate Bio
Biotech Stock Roundup: REGN's Cancer Drug Positive, COVID-19 Updates From NVAX & More
by Zacks Equity Research
The biotech sector was in focus last week with vaccine and antibody updates from quite a few companies like Novavax (NVAX) and Vir (VIR), among others.
Sanofi (SNY)/Translate Bio COVID-19 Vaccine in Clinical Stage
by Zacks Equity Research
The phase I/II clinical study on Sanofi (SNY)/Translate Bio's (TBIO) COVID-19 vaccine candidate will assess its safety, immune response and reactogenicity.
Translate Bio, Inc. (TBIO) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Translate Bio, Inc. (TBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sanofi (SNY) Q4 Earnings & Sales Miss, 2021 EPS View Bright
by Zacks Equity Research
Sanofi's (SNY) Q4 earnings and sales miss estimates. Dupixent drives sales growth in the quarter
6 Biotech/Drug Stocks Up Manifold in 2020 Thanks to COVID-19
by Zacks Equity Research
We discuss six biotech/drug stocks, NVAX, VXRT, MRNA, TBIO, INO and BNTX that have more than doubled in 2020 on the back of their progress in coronavirus vaccine development.
The Zacks Analyst Blog Highlights: INO, NVAX, TBIO and VXRT
by Zacks Equity Research
The Zacks Analyst Blog Highlights: INO, NVAX, TBIO and VXRT
4 Biotechs Likely to Gain on Coronavirus Vaccine Efforts
by Indrajit Bandyopadhyay
In the race to develop a coronavirus vaccine, Pfizer and its partner BioNTech have a lead, closely followed by Moderna. However, four other biotechs, NVAX, TBIO, INO and VXRT, still hold potential to gain from their vaccine development efforts.
Sanofi's (SNY) Meningitis Vaccine MenQuadfi Wins EU Approval
by Zacks Equity Research
The European Commission nods to Sanofi's (SNY) MenQuadfi, a meningococcal vaccine for individuals, aged 12 months and older.
Find Strong Stocks with this First Profit Screener
by Benjamin Rains
Let's use our 'First Profit' screener to help find stocks that investors might want to consider buying after they posted positive earnings for the first time ever, or for some time...
Sanofi's (SNY) Q3 Earnings & Sales Miss, 2020 View Raised
by Zacks Equity Research
Sanofi's (SNY) earnings and sales miss estimates. It raises its earnings growth expectations for the year.
Sanofi's mRNA Vaccine for Coronavirus to Enter Clinical Stage
by Zacks Equity Research
Sanofi (SNY) and Translate Bio select coronavirus vaccine candidate MRT5500 for clinical development, based on its promising pre-clinical data. A clinical study is anticipated by this year-end.
Sanofi/Glaxo to Supply 70M Coronavirus Vaccine Doses in Canada
by Zacks Equity Research
Sanofi's (SNY) recombinant protein-based technology is being combined with Glaxo's pandemic adjuvant technology to develop an adjuvanted COVID-19 vaccine.
Sanofi/Glaxo to Supply 300M Coronavirus Vaccine Doses in EU
by Zacks Equity Research
Sanofi (SNY) recombinant protein-based technology is being combined with Glaxo's (GSK) pandemic adjuvant technology to develop an adjuvanted COVID-19 vaccine.
What's in Store for Avenue Therapeutics (ATXI) in Q2 Earnings?
by Zacks Equity Research
Avenue Therapeutics' (ATXI) sole pipeline candidate, tramadol, is under review. With lower clinical activities, operating expenses are likely to have declined during the second quarter.
What Awaits Selecta Biosciences (SELB) This Earnings Season?
by Zacks Equity Research
In the absence of any marketed drugs, investor focus is likely to be on Selecta Biosciences' (SELB) lead pipeline candidate, SEL-212 on the second-quarter conference call.
Aldeyra (ALDX) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Aldeyra's (ALDX) pipeline progress will be in focus when it reports Q2 results later in the week.
CytoDyn (CYDY) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
CytoDyn's progress on its lead candidate, leronlimab, will be in focus when it reports Q4 results.
Actinium (ATNM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Actinium's (ATNM) lead candidate, Iomab-B, being evaluated for acute myeloid leukemia will be in focus when the company reports second-quarter earnings.
Onconova (ONTX) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on pipeline updates when Onconova (ONTX) reports Q2 results.
Is a Beat in the Cards for Bristol-Myers' (BMY) Q2 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2020 results.
Teva (TEVA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Teva's (TEVA) second-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products
Has Translate Bio (TBIO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (TBIO) Outperforming Other Medical Stocks This Year?